Conversion of CD73$^{\text{hi}}$FR4$^{\text{hi}}$ anergic T cells to IFN-γ–producing effector cells disrupts established immune tolerance

To the editor: Anergic T (T$_{\text{AN}}$) cells marked by CD73$^{\text{hi}}$FR4$^{\text{hi}}$ have been shown to differentiate to immunosuppressive populations, such as FoxP3$^+$ Tregs or IL-10–producing Tr1 cells (1, 2), and are therefore deemed harmless to stable immune tolerance. However, their potential to differentiate to pathological IFN-γ–producing effector cells has not been studied. We developed an allogeneic transplant tolerance model to investigate this possibility.

We used a BALB/c-to-C57BL/6 (B6) islet transplant model. Donor-specific transplant tolerance was induced in recipients by infusing on days −7 and +1 donor splenocytes treated ex vivo with ethylenecarbodiimide (3) and has been indefinitely maintained in unmanipulated recipients as described previously (4). We first examined the presence of CD73$^{\text{hi}}$FR4$^{\text{hi}}$ T$_{\text{AN}}$ cells intolerized recipients. As shown in Figure 1A, the majority of intragraft CD44$^+$FoxP3$^+$CD4$^+$ T cells were CD73$^{\text{hi}}$FR4$^{\text{hi}}$ T$_{\text{AN}}$ cells. These cells were also present in the spleens of tolerized recipients, albeit less prominently than in allografts. In contrast, there was a significantly smaller T$_{\text{AN}}$ population in the spleens of nontolerized mice.

We next perturbed this stable tolerance on day 95 after transplantation by giving acute murine cytomegalovirus (MCMV) infection to tolerized mice, which has been previously shown to precipitate allograft rejection in approximately 60%–70% recipients over the ensuing 5–6 weeks (5). Interestingly, at the time of rejection, we observed a significant reduction of the number of intragraft CD73$^{\text{hi}}$FR4$^{\text{hi}}$ T$_{\text{AN}}$ cells, along with a significantly reduced level of CD73 and FR4 expression on remaining T$_{\text{AN}}$ cells (Figure 1B). We confirmed that intragraft FoxP3$^+$ Tregs, known to similarly express CD73 and FR4, continued to exhibit the same level of CD73 and FR4 before and after MCMV infection (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI163872DS1).

Next, we determined the fate of CD73$^{\text{hi}}$FR4$^{\text{hi}}$ T$_{\text{AN}}$ cells in response to MCMV infection. In vitro, we FACS-sorted T$_{\text{AN}}$ cells (CD3$^+$CD4$^+$CD44$^+$CD25$^+$CD73$^{\text{hi}}$FR4$^{\text{hi}}$) from spleens of tolerized B6 mice (verified to be indeed anergic; Supplemental Figure 2). We cultured them for 5 days with B6 bone marrow–derived DCs with and without MCMV pretreatment and with and without pulse with BALB/c cell lysate (Supplemental Methods). As shown in Figure 1C, T$_{\text{AN}}$ cells cocultured with MCMV-infected DCs with and without pulse with BALB/c lysates showed a marked downregulation of CD73 and FR4 (P < 0.05), acquired cell surface CD25 expression (data not shown), and began to prominently express the Th1 cytokine IFN-γ among the proliferating (Ki-67$^+$) subset. Interestingly, LPS-treated DCs, in contrast to MCMV-treated DCs, did not lead to any downregulation of CD73 or FR4 on T$_{\text{AN}}$ cells (Supplemental Figure 3). In vivo, we similarly FACS-sorted T$_{\text{AN}}$ cells for CD45.2 mice and transferred them to CD45.1 mice, followed by MCMV infection a day later. As shown in Figure 1D, 1 week after MCMV infection, a substantial portion of the CD45.2$^+$ T$_{\text{AN}}$ cells became CD73 FR4$^-$ and began to produce IFN-γ; in contrast, without MCMV infection, the CD45.2$^+$ T$_{\text{AN}}$ cells remained CD73$^{\text{hi}}$FR4$^+$.

Collectively, these data support that MCMV infection reverts the anergic phenotype of T$_{\text{AN}}$ cells, likely via DCs, and promotes their differentiation to IFN-γ–producing cells.

Finally, we determined the functional significance of T$_{\text{AN}}$ cells in MCMV-mediated disruption of stable tolerance. First, we depleted T$_{\text{AN}}$ cells in stably tolerized recipients with a course of anti-FR4 (clone TH6) from day 95 to 120 (100 μg i.v. every 5 days for 6 doses), followed by MCMV infection on day 125. Using a different clone of anti-FR4 (12A5), we confirmed that this course of anti-FR4 indeed effectively depleted CD4 FR4$^+$ but not other cells (Supplemental Figure 4). As shown in Figure 1E, left, none of the recipients treated with anti-FR4 experienced allograft rejection (followed up to day 150). Furthermore, this treatment with anti-FR4 prior to MCMV infection completely prevented MCMV-precipitated rejection in previously tolerized recipients (Figure 1E, right).

To further corroborate above findings from the anti-FR4 experiment, we adoptively transferred sorted T$_{\text{AN}}$ cells to B6.RAG–/– mice bearing BALB/c islets, followed by MCMV infection and infusion of naive CD8 T cells (Figure 1F, experimental scheme). We first observed that T$_{\text{AN}}$ cells converted to CD73 FR4$^+$ T cells following MCMV infection (Figure 1G). In addition, mice receiving T$_{\text{AN}}$ cells rejected the BALB/c islet allograft following MCMV infection and naive CD8 T cell infusion, whereas mice not receiving T$_{\text{AN}}$ cells did not, despite identical MCMV infection and naive CD8 T cell infusion subsequently (Figure 1H). These data substantiate that the T$_{\text{AN}}$ cells are crucial in driving rejection in MCMV-infected mice.

Findings in this study refute the notion that CD73$^{\text{hi}}$FR4$^{\text{hi}}$ T$_{\text{AN}}$ cells are simply passive cells, innocently present during immune tolerance, and instead support that, when appropriately stimulated, these cells can differentiate to IFN-γ–producing Th1 cells to promote immunity. More importantly, we developed a therapeutic strategy for preserving the stability of tolerance by preemptively depleting T$_{\text{AN}}$ cells prior to immune perturbation. In our model, the CD73$^{\text{hi}}$FR4$^{\text{hi}}$ cells expressed lower levels of the inhibitory molecules CTLA4 and TIGIT in comparison to FoxP3$^+$ Tregs (data not shown), suggesting cell-intrinsic factors that determine their fate in response to external stimuli. Our data also point to cell-extrinsic factors originating from partners that interact with T$_{\text{AN}}$ cells, specifically DCs, that play a critical role in their differentiation to effector cells. Collectively, our findings underscore the potential detrimental of anergic T cells, which may seem benign, in tolerant recipients. Additionally, we support the efforts of future studies to identify crucial elements of anergic T cell instability and therapeutic targets to prevent their differentiation to proinflammatory cells.

Anil Dangi, Irma Husain, Collin Z. Jordan, Shuangjin Yu, and Xunrong Luo

J Clin Invest. 2023;133(5):e163872 https://doi.org/10.1172/JCI163872
The Journal of Clinical Investigation

RESEARCH LETTER

The Journal of Clinical Investigation    RESEARCH LETTER

2

J Clin Invest. 2023;133(5):e163872  https://doi.org/10.1172/JCI163872

Figure 1. Conversion of CD73hiFR4hi anergic T cells to IFN-γ-producing cells disrupts established transplantation tolerance. (A) TAN cells are enriched in islet allografts and spleens of tolerated recipients. n = 6-12 per group. (B) Loss of TAN cells in islet allografts following MCMV infection of stably tolerated recipients. n = 3-9 per group. (C) TAN cells from tolerated recipients are induced to produce IFN-γ by MCMV-infected DCs (representative of 2 independent experiments). (D) In vivo conversion of adoptively transferred CD45.2 TAN cells following MCMV infection of CD45.1 hosts. n = 2-3 per group. (E) Depletion of TAN cells prevents MCMV-mediated transplant tolerance disruption. n = 3-5 per group. (F) Experimental scheme in RAG−/− mice. (G) In vivo conversion of adoptively transferred TAN cells following MCMV infection of RAG−/− (representative of n = 4). (H) Rejection of islet allografts in RAG−/− following TAN adoptive transfer. n = 3-4 per group. *P < 0.05. (A–D) Mann-Whitney test. (E) Log-rank test.
1 Nephrology, Duke University Medical Center, Durham, North Carolina, USA. 2 Organ Transplantation, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.


Address correspondence to: Xunrong Luo, Department of Medicine, 2 Genome Ct, Rm 2019, Durham, North Carolina 22710, USA. Phone: 919.613.1516; Email: xunrong.luo@duke.edu.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2023, Dangi et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: July 25, 2022; Accepted: January 12, 2023; Published: March 1, 2023.

Reference information: *J Clin Invest*. 2023;133(5):e163872

https://doi.org/10.1172/JCI163872.